Promising combo for advanced melanoma trial halted early
NCT ID NCT03957551
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a combination of two drugs, cabozantinib and pembrolizumab, as a first treatment for people with advanced melanoma that had spread. The goal was to see if the combination was safe and could shrink tumors. The trial was stopped early, but the results help guide future research.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED METASTATIC MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Iowa Hospitals and Clinics
Iowa City, Iowa, 52242, United States